VALENCIA, Calif. and MELBOURNE, Australia, Aug. 17, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a ...

Credit: Avita Medical. The RECELL System is a single-use, autologous cell harvesting device. The Food and Drug Administration (FDA) has approved the RECELL ® System for the treatment of vitiligo. The ...

VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (RCEL) (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today ...

AVITA Medical, a regenerative medicine company, is pioneering the RECELL System - a patient-specific skin cell solution aimed at revolutionizing skin restoration. The company saw a 40% increase in ...

Please provide your email address to receive an email when new articles are posted on . Melanocyte-keratinocyte transplant procedures are rare in the U.S. due to a need for specialized equipment. The ...

Please provide your email address to receive an email when new articles are posted on . The RECELL system was successful in repigmenting skin in patients with vitiligo, Avita Medical announced in a ...

VALENCIA, Calif. & MELBOURNE, Australia--(BUSINESS WIRE)--AVITA Therapeutics, Inc. (NASDAQ: RCEL, ASX:AVH), a regenerative medicine company that is developing and commercializing a technology platform ...

VALENCIA, Calif. and MELBOURNE, Australia, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company leading the development and commercialization ...

Global evidence and real-world data demonstrate the clinical, operational, and economic impact of AVITA Medical’s RECELL System across wound types and patient populations VALENCIA, Calif., Nov. 03, ...